Navigation Links
D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
Date:3/4/2008

REHOVOT, Israel, March 4 /PRNewswire/ -- D-Pharm announced today that it has held its Pre-IND (Investigational New Drug) meeting with the FDA to discuss the forthcoming IND submission for DP-b99, a novel drug to aid recovery following acute stroke. The Pre-IND meeting focused on the proposed plans for the Phase III clinical program and the discussion included clinical trials to date, preclinical pharmacology, toxicology data and the FDA requirements and suggestions for the IND submission. DP-b99 is a unique drug protecting brain cells in stroke patients, discovered and developed by D-Pharm.

Alex Kozak, PhD, President and CEO of D-Pharm, said "The positive and constructive feed-back we've received from the FDA is most encouraging. With a number of uncertainties in the developmental program removed we may now follow a clear path towards an IND application for a pivotal Phase III study towards the end of this year. This is good news for D-Pharm and for stroke patients."

Most recently, D-Pharm successfully completed a Phase IIb trial for DP-b99 in 150 ischemic stroke patients. Results from this study will be published shortly in the peer reviewed journal, Stroke. DP-b99 statistically significantly increased by two-fold the percentage of patients that completely recovered from ischemic stroke. In addition, DP-b99 has at least a 9hr therapeutic window and may be safely administered in this patient population.

D-Pharm has commenced preparations for the pivotal Phase III trial, including manufacturing of the drug, certain customary studies and IND submission. The Phase III trial is expected to commence in 2009 and to recruit about 750 moderately severe acute stroke patients in North America, Europe and Asia. D-Pharm will be seeking a suitable CRO for the next study with DP-b99. Interested CROs can find more details by following this link:

http://www.dpharm.com/docs/reports/Call_for_proposals_for_DP-b99_Ph_III _s

tudy.pdf

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

About Stroke

Every year approximately 750,000 Americans have a new or recurrent stroke. The second most common cause of death worldwide, stroke is also the leading cause of serious long-term disability; 15% to 30% of stroke survivors experience permanent disability. According to the American Heart Association, the mean lifetime cost resulting from an ischemic stroke is estimated at $140,000 per patient. Other than tissue plasminogen activator (tPA), which must be administered 3 hours after stroke, there are no FDA approved medicines for this indication.

About D-Pharm Ltd.

D-Pharm (http://www.dpharm.com) is clinical stage biopharmaceutical company pioneering the development of lipid-like therapeutics and has generated a rich pipeline of patent protected proprietary products. D-Pharm's pipeline includes advanced clinical stage products, DP-b99 and DP-VPA, a novel drug for treatment of epilepsy, bipolar disorder and migraine prophylaxis, currently in Phase II development. DP-460 is in preclinical development intended as an oral, disease-modifying therapy for Alzheimer's disease. Other mimics of bioactive lipids, LipidoMimetix, are at an earlier developmental stage, for cancer.

For further information please contact:

Tami Horovitz, PhD.

Tel: +972-8-9385100

Fax: +972-8-9300795

Email: thorovitz@dpharm.com


'/>"/>
SOURCE D-Pharm Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Plurality Completes R&D of its HAL-256 Multicore Processor
2. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
3. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
4. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
5. Cardium Completes $5.3 Million Registered Direct Offering
6. WuXi PharmaTech Completes Acquisition of AppTec
7. Max Nutrition, Inc. Completes Share Exchange with American Spring Pharmaceutical, Inc.
8. Healionics Corporation Completes Series A Financing
9. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
10. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
11. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former senior ... the University of North Carolina Kenan-Flagler Business School effective June 27. ... Kenan-Flagler, with a focus on the school’s international efforts, leading classes and participating ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
Breaking Biology Technology:
(Date:6/2/2016)... LONDON , June 2, 2016 ... Systems, Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & ... intelligence provider visiongain offers comprehensive analysis of ... that this market will generate revenues of $17.98 billion ... Systems acquired DVTEL Inc, a leader in software and ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
Breaking Biology News(10 mins):